Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes

Seattle, WA US
August 4, 2023 to August 5, 2023

This CME-accredited activity, “Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes,” features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
  • Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
  • Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology fellows
  • Oncology nurses
  • NPs/PAs
  • Oncology pharmacists

 

Hotel Information

Grand Hyatt Seattle

A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment. 

To receive the discounted rate, please reserve your room by Friday, July 14, 2023, by visiting the link: www.hyatt.com/en-US/group-booking/

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

PLATINUM SPONSOR

Course summary
Available credit: 
  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.
Course opens: 
03/10/2023
Course expires: 
11/05/2023
Event starts: 
08/04/2023 - 3:15pm PDT
Event ends: 
08/05/2023 - 4:15pm PDT
Cost:
$300.00

Conference Co-Chairs: Dr. Krish Patel and Dr. Mazyar Shadman

Day 1 – August 04, 2023

Times listed are in Pacific Time (PT)
 
02:30 – 03:00 PM: REGISTRATION, EXHIBITS, NETWORKING

03:00 PM - 03:05 PM: Welcome - Krish Patel, MD, and Mazyar Shadman, MD, MPH

03:05 PM - 03:15 PM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


03:15 PM - 05:15 PM: SESSION 1 - UPDATES ON APPROVED CAR T-CELL THERAPIES  

Session Chairs: Krish Patel, MD, and Mazyar Shadman, MD, MPH       

03:15 PM - 03:40 PM: Updates in CAR T-cell Therapy in Lymphoma - David Maloney, MD, PhD

03:40 PM - 04:05 PM: Updates in CAR T-cell Therapy in Myeloma - Andrew Cowan, MD

04:05 PM - 04:30 PM: Updates in CAR T-cell Therapy in ALL - Richard Maziarz, MD

04:30 PM - 05:15 PM: Panel discussion with David Aboulafia, MD, Andrew Cowan, MD, Krishna Komanduri, MDYi Lin, MD, Ph.D., Krish Patel, MD, and Mazyar Shadman, MD, MPH 


05:15 PM - 06:15 PMABSTRACT SESSION **This is a non-CME activity**

Faculty Discussants: Krishna Komanduri, MD, Mazyar Shadman, MD, Krish Patel, MD

05:15 PM - 05:30 PM: Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory chronic lymphocytic leukemia: 6-year follow-up - Emily C. Liang, MD

05:30 PM - 05:45 PM: Access to chimeric antigen T-cell receptor (CAR-T) therapy for patients with Non-Hodgkin Lymphoma (NHL) in Oregon - Somya Khare, BS

05:45 PM - 06:00 PM: Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma - Laura Samples, MD

06:00 PM - 06:15 PM: Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting - Andrew J. Portuguese, MD


DAY 2 – August 05, 2023

07:00 AM - 08:00 AM: REGISTRATION, BREAKFAST, EXHIBITS


08:00 AM - 10:15 AM: SESSION 2 - DEBATES IN DLBCL AND FL

Session Chairs: Mazyar Shadman, MD, MPH, and Richard Maziarz, MD

08:00 AM - 08:10 AM: Case Presentation: Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Emily Liang, MD

08:10 AM - 08:25 AM: DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of CAR TOlalekan O. Oluwole, MBBS, MD

08:25 AM - 08:40 AM: DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Auto-HSCTMazyar Shadman, MD, MPH       

08:40 AM - 08:55 AM: DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Non-cellular Therapy -Tycel Phillips, MD

08:55 AM - 09:10 AM: Discussion

09:10 AM - 09:20 AM: Case presentation: Relapsed/Refractory Follicular Lymphoma (FL) - Laura Samples, MD

09:20 AM - 09:35 AM: FL debate: CAR T versus Mosun versus Other – in favor of CAR TMatthew Ulrickson, MD

09:35 AM - 09:50 AM: FL debate: CAR T versus Mosun versus Other – in favor of MosunNadia Khan, MD

09:50 AM - 10:05 AM: FL debate: CAR T versus Mosun versus Other –in favor of OtherChaitra Ujjani, MD

10:05 AM - 10:15 AM: Discussion


10:15 AM - 10:30 AM: BREAK AND EXHIBITS


10:30 AM - 12:15 PM: SESSION 3 - DEBATES IN MCL AND MYELOMA

Session Chairs: Nadia Khan, MD, and Krishna Komanduri, MD

10:30 AM - 10:40 AM: Case presentation: Relapsed/Refractory Mantle Cell Lymphoma (MCL) - Julia Parker DRNP, AGNP-C

10:40 AM - 10:55 AM: MCL debate: CAR T versus BTKi – in favor of CAR TMatt Lunning, DO

10:55 AM - 11:10 AM: MCL debate: CAR T versus BTKi – in favor of BTKi Alexey Danilov, MD

11:10 AM - 11:20 AM: Case presentation: Relapsed/Refractory Multiple Myeloma (MM) - Josh Epworth, ARNP

11:20 AM - 11:35 AM: Myeloma debate: CAR T versus Teclistimab – in favor of CAR TSwathi Namburi, MD

11:35 AM - 11:50 AM: Myeloma debate: CAR T versus Teclistimab – in favor of Teclistimab - Rahul Banerjee, MD

11:50 AM – 12:15 PM: Discussion 


12:15 PM - 01:15 PM: LUNCH AND EXHIBITS

12:30 PM to 1:15 PM – Product Theater Sponsored by Bristol Myers Squibb - in breakout room Portland I & II

Title:  Advances in second-line therapy in DLBCL for transplant-eligible & transplant-ineligible patients

This is an educational presentation on head-to-head trial vs standard therapy (TRANSFORM) and the only cell therapy pivotal trial to exclusively enroll second-line LBCL patients who were transplant-ineligible (PILOT)

Presenter: Ellen Kim, PharmD, Associate Director, US Medical Lymphoma, Breyanzi, Bristol Myers Squibb


01:15 PM - 02:00 PM: SESSION 4 - ADDRESSING BARRIERS TO CELLULAR THERAPY

Session Chairs: Matt Lunning, DO, and David Aboulafia, MD

01:15 PM - 01:30 PM: Case Presentation: Patient Barriers to Cellular Therapy - Sonia Glennie, ARNP, MSN, OCNand Samuel Jonas, MSW

01:30 PM - 01:45 PM: Allogeneic Cell Therapy: Glimpse of the Future? - Krish Patel, MD

01:45 PM - 02:00 PM: Panel discussion with David Aboulafia, MD, Mazyar Shadman, MD, MPH, and Krish Patel, MD


02:00 PM - 02:15 PMBREAK AND EXHIBITS


02:15 PM - 03:30 PM: SESSION 5 - CELLULAR THERAPY IN LEUKEMIAS

Session Chairs: Richard Maziarz, MD, and Melody Smith, MD, MS

02:15 PM - 02:30 PM: Bispecific Antibody and CAR T Therapy in ALL - What is the right sequence? - Ryan Cassaday, MD

02:30 PM - 02:45 PM: CAR T cell therapy in CLL -Tanya Siddiqi, MD

02:45 PM - 03:00 PM: Cellular Therapy in AML/MDS: Emerging Data - Hany Elmariah, MD

03:00 PM - 03:15 PM: Cellular Therapy in AML: Overcoming Challenges - Naval Daver, MD

03:15 PM - 03:30 PM: Discussion


03:30 PM - 04:15 PM: SESSION 6: CELLULAR THERAPY IN SOLID TUMORS

Session Chairs: Sid Devarakonda, MBBS, MD, and Yi Lin, MD, PhD

03:30 PM - 03:45 PM: Cellular Therapy in Solid Tumors: Emerging Data - Kedar Kirtane, MD

03:45 PM - 04:00 PM: Cellular Therapy in Solid Tumors: Overcoming Challenges - Kelly Paulson, MD, PhD

04:00 PM - 04:15 PM: Discussion


04:15 PM - 04:20 PM: CONCLUDING REMARKS AND ANNOUNCEMENTS

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

A limited number of rooms have been reserved at the Grand Hyatt Seattle for attendees and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment. 

To receive the discounted rate above, please reserve your room by the cut-off date, Friday, July 14, 2023, by using the link below:

https://www.hyatt.com/en-US/group-booking/SEAGH/G-BYTA

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Krish Patel, MD

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Rahul Banerjee, MD, FACP

has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.

Ryan Cassaday, MD

has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Stock Options) with Seagen;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Independent contractor) with Jazz;.
has a financial relationship (Employment) with Seagen;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Grant Or Contract) with Vanda;.
has a financial relationship (Independent contractor) with Pfizer;.

Andrew Cowan, MD

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with BMS;.

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Independent contractor) with Abbvie;.

Naval Daver, MD

has a financial relationship (Other) with Bristol-Meyers Squibb;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Agios;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Trillium;.
has a financial relationship (Grant Or Contract) with Novimmune;.
has a financial relationship (Other) with Daiichi-Sankyo;.
has a financial relationship (Other) with Servier;.
has a financial relationship (Other) with Immunogen;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Bristol-Meyers Squibb;.
has a financial relationship (Other) with Shattuck Labs;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with FATE Therapeutics;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Arog;.
has a financial relationship (Grant Or Contract) with Daiichi-Sankyo;.
has a financial relationship (Other) with Syndax;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Other) with Stemline/Menarini;.
has a financial relationship (Grant Or Contract) with Immunogen;.
has a financial relationship (Grant Or Contract) with Trovagene;.
has a financial relationship (Grant Or Contract) with KITE;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Trillium;.
has a financial relationship (Other) with Celgene;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with KITE;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Hanmi;.
has a financial relationship (Grant Or Contract) with Glycomimmetics;.

Hany Elmariah, MD, MS

has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.

Joshua Epworth, MSN, ARNP

has no relevant financial relationships to disclose at this time.

Sonia Glennie

has a financial relationship (Independent contractor) with SeaGen;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Janssen/PCYC;.

Samuel Jonas, MSW

has no relevant financial relationships to disclose at this time.

Nadia Khan, MD

has a financial relationship (Independent contractor) with Beigene ;.
has a financial relationship (Independent contractor) with Adaptive;.
has a financial relationship (Independent contractor) with PCYC;.

Kedar Kirtane, MD

has a financial relationship (Travel) with A2Bio Therapeutics;.
has a financial relationship (Stock) with Shockwave Medical;.
has a financial relationship (Stock) with Oncternal Therapeutics;.
has a financial relationship (Stock) with Seattle Genetics;.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.

Emily Liang, MD

has no relevant financial relationships to disclose at this time.

Yi Lin

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Boston Scientific ;.
has a financial relationship (Other) with BlueBird Bio;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Fosun Kite;.
has a financial relationship (Other) with NexImmune;.
has a financial relationship (Grant Or Contract) with BlueBird Bio;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Other) with Juno/BMS;.
has a financial relationship (Other) with Gamida Cells;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Sorrento;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Other) with Celgene/BMS;.
has a financial relationship (Other) with Legend BioTech;.
has a financial relationship (Other) with Caribou;.
has a financial relationship (Grant Or Contract) with Kite/Gilead;.
has a financial relationship (Grant Or Contract) with Legend BioTech;.
has a financial relationship (Other) with Kite/Gilead;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Iovance;.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with CRISPR;.
has a financial relationship (Professional Services) with Fate Therapetuics;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Miltenyi;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with EUSA;.
has a financial relationship (Professional Services) with InstilBio;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Curis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Regeneron;.

David Maloney, MD, PhD

has a financial relationship (Stock Options) with A2 Biotherapeutics;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Interius;.
has a financial relationship (Other) with Celgene;.
has a financial relationship (Other) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with Juno therapeutics;.
has a financial relationship (Patent) with Juno Therapeutics/BMS;.
has a financial relationship (Other) with Chimeric Therapeutics;.
has a financial relationship (Other) with Gilead Sciences;.
has a financial relationship (Other) with Caribou Biosciences;.
has a financial relationship (Other) with Juno Therapeutics;.
has a financial relationship (Grant Or Contract) with Kite Pharna;.
has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.
has a financial relationship (Stock Options) with Navan Technologies;.
has a financial relationship (Other) with ImmPACT Bio;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with Mustang Bio;.
has a financial relationship (Grant Or Contract) with Legend Biotech;.

Richard Maziarz, MD

has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Grant Or Contract) with Orca Biotech;.
has a financial relationship (Patent) with Athersys;.
has a financial relationship (Independent contractor) with Artiva;.
has a financial relationship (Independent contractor) with Century Therapeutics;.
has a financial relationship (Independent contractor) with Allovir;.
has a financial relationship (Independent contractor) with Vor Pharma;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Gamida;.

Swathi Namburi, MD

has no relevant financial relationships to disclose at this time.

Olalekan Oluwole

has a financial relationship (Professional Services) with Cargo;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Nektar;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC;.

Julia Parker

has no relevant financial relationships to disclose at this time.

Krish Patel, MD

has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with BeiGene;.

Kelly Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.

Tycel Phillips, MD

has a financial relationship (Independent contractor) with ADCT;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Fencer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Incite;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Eli Lily;.
has a financial relationship (Independent contractor) with Gilead;.

Laura Samples, MD

has no relevant financial relationships to disclose at this time.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with BMS;.

Tanya Siddiqi, Medical Director of Lymphoma City of Hope Orange County, Associate Professor, Director of CLL program, Department of Hematology & Hematopoietic Cell Transplantation

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Gilead/Kite;.
has a financial relationship (Independent contractor) with Beigene;.

Chaitra Ujjani, MD

has a financial relationship (Independent contractor) with Eli Lilly;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Atara;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Pharmacyclics;.
has a financial relationship (Independent contractor) with Epizyme;.

Matthew Ulrickson, MD

has a financial relationship (Independent contractor) with Bristol Meyers Squib;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Travel) with Miltenyi;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Stemline;.
Moderator(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Genetech;.
has a financial relationship (Other) with AZ;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with Merus;.

Nadia Khan, MD

has a financial relationship (Independent contractor) with Adaptive;.
has a financial relationship (Independent contractor) with PCYC;.
has a financial relationship (Independent contractor) with Beigene ;.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.

Yi Lin

has a financial relationship (Other) with Juno/BMS;.
has a financial relationship (Other) with Gamida Cells;.
has a financial relationship (Other) with Fosun Kite;.
has a financial relationship (Other) with NexImmune;.
has a financial relationship (Grant Or Contract) with BlueBird Bio;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Other) with Legend BioTech;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Sorrento;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Other) with Celgene/BMS;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Iovance;.
has a financial relationship (Other) with Caribou;.
has a financial relationship (Grant Or Contract) with Kite/Gilead;.
has a financial relationship (Grant Or Contract) with Legend BioTech;.
has a financial relationship (Other) with Kite/Gilead;.
has a financial relationship (Other) with BlueBird Bio;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Boston Scientific ;.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Curis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with CRISPR;.
has a financial relationship (Professional Services) with Fate Therapetuics;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Miltenyi;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with EUSA;.
has a financial relationship (Professional Services) with InstilBio;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.

Richard Maziarz, MD

has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Gamida;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Grant Or Contract) with Orca Biotech;.
has a financial relationship (Patent) with Athersys;.
has a financial relationship (Independent contractor) with Artiva;.
has a financial relationship (Independent contractor) with Century Therapeutics;.
has a financial relationship (Independent contractor) with Allovir;.
has a financial relationship (Independent contractor) with Vor Pharma;.

Krish Patel, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Kite;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.

Melody Smith, MD, MS

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Stock Options) with A28 Therapeutics;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Novartis;.
Peer reviewer(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.

 

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Industry representatives - $1250

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Attend Only Registration Terms & Conditions:

Employees of companies that have not purchased an exhibit space or are not a sponsor of the conference should refrain from interacting with healthcare provider attendees outside of the main meeting room. This applies to ALL interactions except for asking content-relevant questions to faculty inside the meeting room where the CME-accredited activity occurs. Please do not engage in product promotion activity with any attendees or faculty of the conference. 

If your company has not purchased an exhibit space or sponsorship, and you engage in any promotional activity, including but not limited to introducing yourself to healthcare providers as an employee of the company, handing out business cards and product brochures/flyers, setting up visits/appointments, inviting them to promotional talks, etc., we will invoice YOU for the full cost of a premium exhibit table.

If your company has not purchased an exhibit space or sponsorship, please limit your interaction with healthcare providers attending this conference to "hello" only if you know the provider. Failure to comply with this requirement may result in being banned from all future conferences.

Employees of companies who are not exhibiting or sponsoring the conference may not enter the exhibit area. The exhibit area is ONLY for exhibitors and sponsors to engage in sales activity. Many of our conferences have meals in the exhibit hall; if the meal is in the exhibit hall, you will need to make alternative arrangements for your meals as you will not be provided meals by the meeting.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post-tests as well as course evaluations.